Clinical trials: Triple Negative Breast Cancer, open to volunteers
Epithelial Tumors, Malignant
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
- Trial name
- MYE Symphony (NCT05969041)
- Testing
- MT-302 (A)
- Where
- 6 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Myeloid Therapeutics
Triple Negative Breast Cancer
Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer
The purpose of this study is to assess the efficacy and safety of Cadonilimab (AK104) plus Eribulin compared to the efficacy and safety of Eribulin monotherapy in the treatment of adult patients with recurrent, or metastatic…
- Trial name
- NCT06202313
- Testing
- Cadonilimab, Eribulin
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Shengjing Hospital
Metastatic Triple-Negative Breast Carcinoma
Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
This is a prospective, multicenter, phase I/II, open-label, two-stage design of PD1+ TILs infusion in metastatic or advanced TNBC. TILS001 includes 3 parts.
- Trial name
- TILS001 (NCT05451784)
- Testing
- PD1+ TILs (NUMARZU-001) product infusion
- Where
- 4 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Fundacio Clinic Barcelona
TNBC - Triple-Negative Breast Cancer
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study
This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of Utidelone plus Tirelizumab and Bevacizumab for advanced or metastatic triple-negative breast cancer (TNBC).
- Trial name
- UTILIZABLE (NCT06125080)
- Testing
- Utidelone, Tirelizumab, Bevacizumab
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Huihua Xiong
Triple Negative Breast Cancer
Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
Patients with stage II-III Triple negative breast cancer (TNBC) candidates to receive neoadjuvant chemotherapy (NACT) +/- immune checkpoint inhibitor (ICI) will be included.
- Trial name
- PORTRAIT (NCT05916755)
- Testing
- Whole Genome Sequencing, RNA-Sequencing, Microbiome analysis
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Triple-negative Breast Cancer
Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer
The goal of this clinical trial is to learn about the efficacy and safety of short-term sintilimab in combination with taxane and carboplatin for neoadjuvant therapy in female early-stage triple-negative breast caner patients…
- Trial name
- NeoSTEP (NCT05843292)
- Testing
- Taxane and Carboplatin, Short-term Sintilimab, Surgery
- Volunteers
- 48 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Triple Negative Breast Cancer
Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)
The purpose of this study is to evaluate the efficacy and safety of camrelizumab in combination with apatinib and chemotherapy as neoadjuvant therapy in participants with triple negative breast cancer (TNBC).
- Trial name
- NCT05447702
- Testing
- Camrelizumab, Apatinib, Nab-paclitaxel
- Where
- China
- Volunteers
- 35 people
- Sponsor
- West China Hospital
Clear Cell Renal Cell Carcinoma Metastatic, TNBC - Triple-Negative Breast Cancer
Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours
Carbonic anhydrase IX (CA IX) has been implicated in the progression of most solid tumours and expression has been demonstrated in clinical samples from a variety of solid cancers.
- Conditions
- Clear Cell Renal Cell Carcinoma Metastatic, TNBC - Triple-Negative Breast Cancer, Head and Neck Cancer, Non-small-cell Lung Carcinoma
- Trial name
- CAMP1 (NCT05698238)
- Testing
- CA9hu-1
- Volunteers
- 50 people
- Sponsor
- Mabpro, a.s.
Triple-negative Breast Cancer
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
Positive circulating tumor DNA(ctDNA) status is associated with worse prognosis in breast cancer, especially triple-negative breast cancer(TNBC).
- Trial name
- Apollo (NCT04501523)
- Testing
- Tislelizumab, capecitabine
- Where
- China
- Volunteers
- 460 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line.
- Conditions
- Triple Negative Breast Cancer, Hormone-Resistant Breast Cancer, Non Small Cell Lung Cancer, Mesothelioma
- Trial name
- NCT05627960
- Testing
- AG-01 Compound
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- A&G Pharmaceutical Inc.
Breast Cancer
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
This neoadjuvant trial for patients with TNBC and/or gBRCA breast cancer, aims to investigate the safety and efficacy (improvement in pathological Complete Response at surgery) of concurrent platinum-based chemotherapy with…
- Trial name
- PARTNER (NCT03150576)
- Testing
- Olaparib, Paclitaxel and Carboplatin
- Where
- 30 sites in United Kingdom
- Volunteers
- 780 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Breast Cancer, TNBC - Triple-Negative Breast Cancer
Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer
18F-Fluoroestradiol (18F-FES) is an estrogen receptor-targeting positron emission tomography tracer with high sensitivity and specificity for the detection of estrogen receptor（ER）-positive tumors .
- Conditions
- Breast Cancer, TNBC - Triple-Negative Breast Cancer, Estrogen-receptor-negative Breast Cancer
- Trial name
- NCT05541367
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tongji Hospital
Non-Small-Cell Lung Carcinoma, Malignant Melanoma
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
The microbiome has the potential to serve as a robust biomarker of clinical response to immunotherapy. Additionally, microbial manipulation, through diet, exercise, prebiotics, probiotics, or microbially-derived metabolites, may…
- Conditions
- Non-Small-Cell Lung Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Triple-Negative Breast Cancer
- Trial name
- PARADIGM (NCT05037825)
- Testing
- Checkpoint Inhibitor, Immune
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- VastBiome
Triple Negative Breast Neoplasms
Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study
CAREGIVER is a prospective, randomized, multicenter, open, five-arm study with unequal allocation ratios of 1:1:2:1:2 (palbociclib : paclitaxel : palbociclib + paclitaxel : carboplatin : carboplatin + paclitaxel).
- Trial name
- CAREGIVER (NCT05067530)
- Testing
- Palbociclib, Paclitaxel, Carboplatin
- Where
- 6 sites in Poland
- Volunteers
- 126 people
- Sponsor
- Medical University of Gdansk
Triple Negative Breast Cancer
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy
This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes…
- Trial name
- NCT04437160
- Testing
- Epirubicin or Pirarubicin, Cyclophosphamide
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Chinese Academy of Medical Sciences
Triple Negative Breast Cancer
to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)
This study is a randomized, double-Blind,international multi-Centre, phase III clinical study to evaluate efficacy and safety of HLX10 in combination with chemotherapy versus placebo in combination with chemotherapy as…
- Trial name
- NCT04301739
- Testing
- HLX10, nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide
- Volunteers
- 522 people
- Sponsor
- Shanghai Henlius Biotech
Breast Cancer, Triple Negative Breast Cancer
Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy
This study evaluates whether SLNB can safely be omitted in breast cancer patients with HER2+ or TN tumors who achieve a radiological complete response on MRI after neoadjuvant systemic therapy
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, Sentinel Lymph Node
- Trial name
- ASICS (NCT04225858)
- Testing
- Omission of sentinel lymph node biopsy
- Volunteers
- 340 people
- Sponsor
- The Netherlands Cancer Institute